Long/short equity, biotech, healthcare, small-cap

Synageva: A Strong Candidate For Your Portfolio

Healthcare companies dealing with rare diseases are significant for investors. These companies have a direct and favorable regulatory pathway for drug approval, and once approved the fear of generics or competition becomes less. Synageva Biopharma (NASDAQ:GEVA) is a good example of this. Its lead pipeline candidate, Sebelipase Alfa, is in Phase III development for lysosomal acid lipase, or LAL, deficiency. I see Sebelipase Alfa as a low risk development applicant with a $600 million market potential. Sebelipase Alfa, along with a broad pipeline of other applicants for rare diseases, makes Synageva an attractive investment for long-term growth.

Rare and ultra-rare diseases like Lysosomal Storage Disorders, or LSDs, Mucopolysaccharidosis, or MPS, and TTR-mediated amyloidosis, or ATTR, generally have...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details